Kedar N. Prasad
Research Subjects
Kedar N. Prasad has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Stephen C. Bondy
Department of Occupational and Environmental Medicine and Department of Medicine, University of California Irvine, Irvine, California, USA
4 shared publications- Francisco G. La Rosa
Department of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA
2 shared publications - Stephen Claude Bondy
University of California, Irvine, USA
2 shared publications A. Vernadakis
Department of Psychiatry and Pharmacology, School of Medicine, University of Colorado, Health Sciences Center, 4200 E. 9th Avenue, Denver, CO 80262-0276, USA
1 shared publicationAlicia R. Hovland
Center for Vitamins and Cancer Research and Department of Radiology, College of Medicine, University of Colorado Health Sciences Center, Campus Box C-278, 4200 E. Ninth Avenue, 80262, Denver, Colorado
1 shared publicationAmy J. Hanson
University of Colorado Health Sciences Center
1 shared publication
Latest Publications
- Open Access
- 12 August 2025
- Published by Herald Scholarly Open Access
- Vol. 9 (1) , 1-9
Role of a Micronutrient Mixture, Probiotics, Collagen Peptides, Omega 3, and CBD in Prevention and Improved Treatment of Parkinson’s Disease
Parkinson’s Disease (PD) is a slow, progressive, incurable neurological disorder of the central nervous system which exhibits motor symptoms like tremor, rigidity, and bradykinesia (slowed movement) and nonmotor symptoms such as depression, anxiety, constipation, fatigue, cognitive decline, and sleep disorders.
- 12 August 2025
- Published by Herald Scholarly Open Access
- Vol. 9 (1) , 1-9
Open AccessRole of a Micronutrient Mixture, Probiotics, Collagen Peptides, Omega 3, and CBD in Prevention and Improved Treatment of Parkinson’s Disease
Parkinson’s Disease (PD) is a slow, progressive, incurable neurological disorder of the central nervous system which exhibits motor symptoms like tremor, rigidity, and bradykinesia (slowed movement) and nonmotor symptoms such as depression, anxiety, constipation, fatigue, cognitive decline, and sleep disorders.
- 3 February 2023
- Published by Taylor & Francis in Journal of the American Nutrition Association
- Vol. 42 (8) , 1-7
Discovery of Alpha-Tocopheryl Succinate as a Cancer Treatment Agent Led to the Development of Methods to Potentially Improve the Efficacy of Cancer Therapy
The discovery of alpha-tocopheryl succinate (alpha-TS) as a cancer therapeutic agent markedly stimulated research with or without tumor therapeutic agents on cancer cells and normal cells. Results showed that alpha-TS treatment induced apoptosis in cancer cells and enhanced the apoptotic effects of tumor therapeutic agents on tumor cells in a synergistic manner without affecting the growth of normal cells. Liposomal alpha-TS was more effective than alpha-TS. Some tumors are difficult to treat with chemotherapeutic agents while some become resistant of such treatment. Using a nanotechnology technique, it was demonstrated that alpha-TS conjugated with a chemotherapeutic agent enhanced the levels of apoptosis and restored the sensitivity of tumor cells to that chemotherapeutic agent. The mechanisms of action of alpha-TS alone or in combination with therapeutic agents include the following: (a) inhibition of the expression of oncogenes C-myc and H-ras; (b) alterations in the levels of expression of numerous genes; (c) activation of caspases; (d) inhibition of angiogenesis; (e) destabilization of mitochondria and lysosomes; (f) inhibition of production of production of prostaglandin E2 (PGE2) and PGE2-mediated pro-inflammatory responses; (g) reduction of survivin signaling pathway; and (h) reduction of CD47 expression on the tumor cell surface causing enhancement of phagocytic activity of macrophages leading to engulfment of tumor cells. Despite impressive results in cell culture and in animal models, no studies with alpha-TS alone or in combination with cancer therapeutic agents in human cancer resistant to these therapies have been performed.
- 3 February 2023
- Published by Taylor & Francis in Journal of the American Nutrition Association
- Vol. 42 (8) , 1-7
Discovery of Alpha-Tocopheryl Succinate as a Cancer Treatment Agent Led to the Development of Methods to Potentially Improve the Efficacy of Cancer Therapy
The discovery of alpha-tocopheryl succinate (alpha-TS) as a cancer therapeutic agent markedly stimulated research with or without tumor therapeutic agents on cancer cells and normal cells. Results showed that alpha-TS treatment induced apoptosis in cancer cells and enhanced the apoptotic effects of tumor therapeutic agents on tumor cells in a synergistic manner without affecting the growth of normal cells. Liposomal alpha-TS was more effective than alpha-TS. Some tumors are difficult to treat with chemotherapeutic agents while some become resistant of such treatment. Using a nanotechnology technique, it was demonstrated that alpha-TS conjugated with a chemotherapeutic agent enhanced the levels of apoptosis and restored the sensitivity of tumor cells to that chemotherapeutic agent. The mechanisms of action of alpha-TS alone or in combination with therapeutic agents include the following: (a) inhibition of the expression of oncogenes C-myc and H-ras; (b) alterations in the levels of expression of numerous genes; (c) activation of caspases; (d) inhibition of angiogenesis; (e) destabilization of mitochondria and lysosomes; (f) inhibition of production of production of prostaglandin E2 (PGE2) and PGE2-mediated pro-inflammatory responses; (g) reduction of survivin signaling pathway; and (h) reduction of CD47 expression on the tumor cell surface causing enhancement of phagocytic activity of macrophages leading to engulfment of tumor cells. Despite impressive results in cell culture and in animal models, no studies with alpha-TS alone or in combination with cancer therapeutic agents in human cancer resistant to these therapies have been performed.
- 4 July 2021
- Published by Taylor & Francis in Journal of the American Nutrition Association
- Vol. 41 (5) , 489-498
Can a Micronutrient Mixture Delay the Onset and Progression of Symptoms of Single-Point Mutation Diseases?
Single-point mutation diseases in which substitution of one nucleotide with another in a gene occurs include familial Alzheimer’s disease (fAD), familial Parkinson’s disease (fPD), and familial Creutzfeldt-Jacob disease (fCJD) as well as Huntington’s disease (HD), sickle cell anemia, and hemophilia. Inevitability of occurrence of these diseases is certain. However, the time of appearance of symptoms could be influenced by the diet, environment, and possibly other genetic factors. There are no effective approaches to delay the onset or progression of symptoms of these diseases. The fact that increased oxidative stress and inflammation significantly contribute to the initiation and progression of these point mutation diseases shows that antioxidants could be useful. The major objectives are (a) to present evidence that increased oxidative stress and chronic inflammation are associated with selected single-point mutation diseases, such as fAD, fPD, and fCJD, HD, sickle cell anemia, and hemophilia; (b) to describe limited studies on the role of individual antioxidants in experimental models of some of these diseases; and (c) to discuss a rationale for utilizing a comprehensive mixture of micronutrients, which may delay the development and progression of symptoms of above diseases by simultaneously reducing oxidative and inflammatory damages.
- 4 July 2021
- Published by Taylor & Francis in Journal of the American Nutrition Association
- Vol. 41 (5) , 489-498
Can a Micronutrient Mixture Delay the Onset and Progression of Symptoms of Single-Point Mutation Diseases?
Single-point mutation diseases in which substitution of one nucleotide with another in a gene occurs include familial Alzheimer’s disease (fAD), familial Parkinson’s disease (fPD), and familial Creutzfeldt-Jacob disease (fCJD) as well as Huntington’s disease (HD), sickle cell anemia, and hemophilia. Inevitability of occurrence of these diseases is certain. However, the time of appearance of symptoms could be influenced by the diet, environment, and possibly other genetic factors. There are no effective approaches to delay the onset or progression of symptoms of these diseases. The fact that increased oxidative stress and inflammation significantly contribute to the initiation and progression of these point mutation diseases shows that antioxidants could be useful. The major objectives are (a) to present evidence that increased oxidative stress and chronic inflammation are associated with selected single-point mutation diseases, such as fAD, fPD, and fCJD, HD, sickle cell anemia, and hemophilia; (b) to describe limited studies on the role of individual antioxidants in experimental models of some of these diseases; and (c) to discuss a rationale for utilizing a comprehensive mixture of micronutrients, which may delay the development and progression of symptoms of above diseases by simultaneously reducing oxidative and inflammatory damages.
- Open Access
- 5 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (21) , 8302
Alternatives to Insulin for the Regulation of Blood Sugar Levels in Type 2 Diabetes
This short overview focuses on the causation and treatment of type 2 diabetes (T2D). Emphasis is given to the historical basis of understanding this disease and the background leading to emergence of the central role of insulin. The strengths of insulin administration in the treatment of diabetes are profound, but these need to be balanced against several serious shortcomings of its extended use. Some alternative approaches to T2D management are considered. Insulin is no longer considered as the first choice for type 2 diabetes, and an expanding range of new therapeutic possibilities is emerging. While these may lack the potency of insulin, at a minimum, they allow a major reduction in the intensity of insulin use. In view of the rising worldwide incidence of this disease, it is imperative to develop safe and inexpensive means of limiting its potential for impairment of normal functioning.
- 5 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (21) , 8302
Open AccessAlternatives to Insulin for the Regulation of Blood Sugar Levels in Type 2 Diabetes
This short overview focuses on the causation and treatment of type 2 diabetes (T2D). Emphasis is given to the historical basis of understanding this disease and the background leading to emergence of the central role of insulin. The strengths of insulin administration in the treatment of diabetes are profound, but these need to be balanced against several serious shortcomings of its extended use. Some alternative approaches to T2D management are considered. Insulin is no longer considered as the first choice for type 2 diabetes, and an expanding range of new therapeutic possibilities is emerging. While these may lack the potency of insulin, at a minimum, they allow a major reduction in the intensity of insulin use. In view of the rising worldwide incidence of this disease, it is imperative to develop safe and inexpensive means of limiting its potential for impairment of normal functioning.
- 6 October 2020
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (4) , 406-413
Attenuation of acute and chronic inflammation using compounds derived from plants
The appearance of excessive inflammatory activity is associated with onset of many disease states. Such non-productive responses are often the basis of the mortality consequent to incurring numerous disorders. The current outbreak of coronavirus disease 2019 caused by the virus “severe acute respiratory syndrome coronavirus 2” is a striking reflection of the inadequacy of current medical science to adequately address this issue. The usefulness of a range of materials of botanical origin in the attenuation of both chronic and acute inflammatory responses to various disease stressors is described. The properties of preparations of plant-based origin often parallel those of synthesized pharmacologics, but differ from them in some key respects. These differences can lead to more traditional preparations having distinct therapeutic advantages but also a number of specific shortcomings. The strengths and weaknesses of these materials are objectively contrasted with that of a more orthodox pharmacological approach. Each of these emphases in style has specific advantages and they should not be considered as competitors, but rather as accomplices in combating adverse states involving derangement of immune function.
- 6 October 2020
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (4) , 406-413
Attenuation of acute and chronic inflammation using compounds derived from plants
The appearance of excessive inflammatory activity is associated with onset of many disease states. Such non-productive responses are often the basis of the mortality consequent to incurring numerous disorders. The current outbreak of coronavirus disease 2019 caused by the virus “severe acute respiratory syndrome coronavirus 2” is a striking reflection of the inadequacy of current medical science to adequately address this issue. The usefulness of a range of materials of botanical origin in the attenuation of both chronic and acute inflammatory responses to various disease stressors is described. The properties of preparations of plant-based origin often parallel those of synthesized pharmacologics, but differ from them in some key respects. These differences can lead to more traditional preparations having distinct therapeutic advantages but also a number of specific shortcomings. The strengths and weaknesses of these materials are objectively contrasted with that of a more orthodox pharmacological approach. Each of these emphases in style has specific advantages and they should not be considered as competitors, but rather as accomplices in combating adverse states involving derangement of immune function.
- Open Access
- 18 August 2020
- Published by Taylor & Francis
- p. 61-89
Modifications of Cellular Radiation Damage
- 18 August 2020
- Published by Taylor & Francis
- p. 61-89
Open AccessModifications of Cellular Radiation Damage
- Open Access
- 18 August 2020
- Published by Taylor & Francis
- p. 123-151
Radiation Syndromes and Their Modifications
- 18 August 2020
- Published by Taylor & Francis
- p. 123-151
Open AccessRadiation Syndromes and Their Modifications
- Open Access
- 18 August 2020
- Published by Taylor & Francis
- p. 253-261
Radiation Carcinogenesis: Animal Model
- 18 August 2020
- Published by Taylor & Francis
- p. 253-261
Open AccessRadiation Carcinogenesis: Animal Model